Rocket Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RCKT) $25.92 +0.61 (+2.41%) (As of 01:27 PM ET) Add Compare Share Share Today's Range$25.10▼$26.5550-Day Range$16.78▼$25.3152-Week Range$14.89▼$26.55Volume668,559 shsAverage Volume898,282 shsMarket Capitalization$2.34 billionP/E RatioN/ADividend YieldN/APrice Target$50.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Rocket Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside91.4% Upside$50.38 Price TargetShort InterestBearish10.08% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.02Based on 4 Articles This WeekInsider TradingSelling Shares$677,083 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.03) to ($2.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.38 out of 5 starsMedical Sector223rd out of 949 stocksPharmaceutical Preparations Industry87th out of 408 stocks 3.5 Analyst's Opinion Consensus RatingRocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.38, Rocket Pharmaceuticals has a forecasted upside of 91.4% from its current price of $26.32.Amount of Analyst CoverageRocket Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.08% of the outstanding shares of Rocket Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently increased by 0.44%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Rocket Pharmaceuticals is -0.81. Previous Next 2.2 News and Social Media Coverage News SentimentRocket Pharmaceuticals has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Rocket Pharmaceuticals this week, compared to 9 articles on an average week.Search Interest12 people have searched for RCKT on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.MarketBeat Follows6 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $677,083.00 in company stock.Percentage Held by Insiders31.10% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.49% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($3.03) to ($2.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -8.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -8.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.Read More RCKT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCKT Stock News HeadlinesDecember 5, 2023 | seekingalpha.comRocket Pharmaceuticals: Promising, But Not A Rocket At This ValuationDecember 4, 2023 | yahoo.comGuardians of the Galaxy Vol. 3’s Bradley Cooper Talks Personal Grief in Rocket Raccoon PerformanceDecember 6, 2023 | Edge On The Street (Ad)Energy Storage Trend Ignites Frenzy Over Vanadium SupplyAs the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.December 4, 2023 | usnews.comSouth Korea Tests Solid-Fuel Rocket Amid Space Race With North KoreaDecember 3, 2023 | americanbankingnews.comRocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 3.2%November 28, 2023 | msn.comAvenged Sevenfold to make stop at Cleveland's Rocket Mortgage FieldHouse in 2024November 27, 2023 | msn.comLaval Rocket Wanted More from Trip | Rocket NotepadNovember 21, 2023 | usnews.comTwo Reporters, Third Person Killed in Rocket Strike Near Lebanon-Israel Border - State MediaDecember 6, 2023 | Financial Alphas (Ad)Lithium Discovery So BIG You Can't Miss it, Even From SpaceWith the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!November 10, 2023 | msn.comIndie pop trio AJR coming to Rocket Mortgage FieldHouse in Summer 2024November 9, 2023 | news.yahoo.comLaunch contracts are "basically worthless" until a rocket is proven and flying, Rocket Lab CEO saysNovember 9, 2023 | finance.yahoo.comWall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?November 9, 2023 | yahoo.comKachow! Lightning McQueen is now in Rocket LeagueNovember 9, 2023 | msn.comLightning McQueen has Arrived to Rocket LeagueNovember 8, 2023 | techcrunch.comRocket Lab’s Electron launch vehicle “fully” booked next year, will resume flight as early as November-endNovember 8, 2023 | markets.businessinsider.comPositive 3Q Results and Robust Financial Position Drive Buy Rating for Rocket Pharmaceuticals with Increased 2024 Price TargetNovember 7, 2023 | markets.businessinsider.comRocket Pharmaceuticals: Promising Pivotal Studies, Undervalued Potential and Robust Financial Health Encourage Buy RatingNovember 7, 2023 | yahoo.comRocket League Lightning McQueen DLC Revealed, Release Date SetNovember 4, 2023 | msn.com4 takeaways from chat with Rocket Companies exec on calling workers back to officeNovember 3, 2023 | msn.comUToledo alumnus returns to Ohio to shoot debut feature film with help from another former RocketNovember 2, 2023 | msn.comRocket Companies ekes out 3rd quarter profit amid high mortgage ratesNovember 2, 2023 | msn.comGeaux Rocket Ride becomes the second Breeders’ Cup horse to die in two daysNovember 2, 2023 | usatoday.comGeaux Rocket Ride is second horse based at Santa Anita to die in lead up to Breeders' CupNovember 1, 2023 | msn.comHaskell winner Geaux Rocket Ride euthanized after Breeders' Cup training injuryNovember 1, 2023 | sports.yahoo.comAnother step forward: Rocket Sanders bumped to likely for Florida gameOctober 28, 2023 | msn.comRocket Shut Out in Syracuse | RECAP: LAV @ SYROctober 28, 2023 | msn.comSyracuse Crunch shut out Rocket, 5-0See More Headlines Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RCKT CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees240Year Founded2018Price Target and Rating Average Stock Price Target$50.38 High Stock Price Target$65.00 Low Stock Price Target$35.00 Potential Upside/Downside+91.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-221,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.40% Return on Assets-47.51% Debt Debt-to-Equity Ratio0.04 Current Ratio13.35 Quick Ratio13.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.47 per share Price / Book4.07Miscellaneous Outstanding Shares90,160,000Free Float62,120,000Market Cap$2.37 billion OptionableOptionable Beta1.02 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Gaurav D. Shah M.D. (Age 48)CEO & Director Comp: $1.05MMs. Kinnari Patel M.B.A. (Age 44)Pharm.D., President & COO Comp: $849.93kMr. John C. Militello CPA (Age 50)VP, Senior Controller, Treasurer, Principal Accounting Officer & Interim Principal Financial Officer Comp: $501.42kMr. Mayo Pujols (Age 54)Chief Technical Officer & Executive VP Comp: $649.71kMr. Raj Prabhakar M.B.A. (Age 49)Senior VP & Chief Business Officer Comp: $619.13kMr. Martin Louis Wilson J.D. (Age 47)General Counsel, Chief Compliance Officer & Senior VP Comp: $149.95kKevin GiordanoDirector of Corporate CommunicationsMs. Isabel Carmona J.D.Senior VP & Chief Human Resources OfficerMr. Jonathan Schwartz M.D. (Age 58)Chief Gene Therapy Officer & Senior VP of Clinical Development Comp: $557.79kDr. Gayatri R. Rao J.D.M.D., Chief Development Officer of LVV & Senior VPMore ExecutivesKey CompetitorsSchrödingerNASDAQ:SDGRCymaBay TherapeuticsNASDAQ:CBAYCrinetics PharmaceuticalsNASDAQ:CRNXIndiviorNASDAQ:INDVRhythm PharmaceuticalsNASDAQ:RYTMView All CompetitorsInsiders & InstitutionsCitigroup Inc.Bought 75,071 shares on 12/6/2023Ownership: 0.179%Wellington Management Group LLPBought 2,880,373 shares on 12/1/2023Ownership: 8.898%Comerica BankBought 440,076 shares on 11/21/2023Ownership: 0.488%Wolverine Trading LLCBought 19,000 shares on 11/16/2023Ownership: 0.000%Harbour Investments Inc.Bought 2,230 shares on 11/16/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions RCKT Stock Analysis - Frequently Asked Questions Should I buy or sell Rocket Pharmaceuticals stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCKT shares. View RCKT analyst ratings or view top-rated stocks. What is Rocket Pharmaceuticals' stock price target for 2024? 9 Wall Street research analysts have issued twelve-month price objectives for Rocket Pharmaceuticals' stock. Their RCKT share price targets range from $35.00 to $65.00. On average, they anticipate the company's stock price to reach $50.38 in the next year. This suggests a possible upside of 91.4% from the stock's current price. View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts. How have RCKT shares performed in 2023? Rocket Pharmaceuticals' stock was trading at $19.57 at the beginning of the year. Since then, RCKT stock has increased by 34.5% and is now trading at $26.32. View the best growth stocks for 2023 here. When is Rocket Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our RCKT earnings forecast. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($0.75) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.06. During the same period in the previous year, the business posted ($0.87) EPS. What ETFs hold Rocket Pharmaceuticals' stock? ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Harbor Health Care ETF (MEDI), Harbor Disruptive Innovation ETF (INNO) and Putnam BioRevolution ETF (SYNB).Franklin Genomic Advancements ETF (HELX). What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA). Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (8.90%), Westfield Capital Management Co. LP (4.65%), Avidity Partners Management LP (1.76%), Bamco Inc. NY (1.23%), Assenagon Asset Management S.A. (1.09%) and JPMorgan Chase & Co. (0.85%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RCKT) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.